By contrast, HAEC is a relatively poorly studied intestinal inflammatory disorder in children with clinical features similar to pediatric IBD. At present little attention has been given to the exploring the similarities in immune responses in HAEC patients to IBD patients. Our aim is to measure a panel of antibodies routinely used for IBD patients, and compare HD patients with and without HAEC. One or more antibody levels may serve as a biomarker for HD patients at risk of developing HAEC.